[1]
|
中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版) [J]. 中华结核和呼吸杂志, 2020, 43(11): 918-946.
|
[2]
|
Brown-Elliott, B.A. and Woods, G.L. (2019) Antimycobacterial Susceptibility Testing of Nontu-berculous Mycobacteria. Journal of Clinical Microbiology, 57, e00834-19. https://doi.org/10.1128/JCM.00834-19
|
[3]
|
Prevots, D.R. and Marras, T.K. (2015) Epidemiology of Human Pul-monary Infection with Nontuberculous Mycobacteria: A Review. Clinics in Chest Medicine, 36, 13-34. https://doi.org/10.1016/j.ccm.2014.10.002
|
[4]
|
Jones, M.M., Winthrop, K.L., Nelson, S.D., et al. (2018) Epidemi-ology of Nontuberculous Mycobacterial Infections in the U.S. Veterans Health Administration. PLOS ONE, 13, e0197976. https://doi.org/10.1371/journal.pone.0197976
|
[5]
|
唐神结. 非结核分枝杆菌病诊断与治疗专家共识解读[J]. 中国医刊, 2016, 51(3): 21-24.
|
[6]
|
Falkinham, J.O. (2007) Growth in Catheter Biofilms and Antibiotic Re-sistance of Mycobacterium avium. Journal of Medical Microbiology, 56, 250-254. https://doi.org/10.1099/jmm.0.46935-0
|
[7]
|
Griffith, D.E., Aksamit, T., Brown-Elliott, B.A., et al. (2007) An Offi-cial ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. American Journal of Respiratory and Critical Care Medicine, 175, 367-416. https://doi.org/10.1164/rccm.200604-571ST
|
[8]
|
Haworth, C.S. and Floto, R.A. (2017) Introducing the New BTS Guideline: Management of Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD). Thorax, 72, 969-970. https://doi.org/10.1136/thoraxjnl-2017-210929
|
[9]
|
Pérez-García, F., Ruiz-Serrano, M.J., López Roa, P., et al. (2017) Diagnostic Performance of Anyplex II MTB/MDR/XDR for Detection of Resistance to First and Second Line Drugs in Mycobacterium tuberculosis. Journal of Microbiological Methods, 139, 74-78. https://doi.org/10.1016/j.mimet.2017.05.006
|
[10]
|
马进宝, 马婷婷, 任斐. 阿米卡星在耐多药结核病治疗中引起耳毒性研究进展[J]. 中国热带医学, 2020, 20(3): 288-290.
|
[11]
|
Kumar, K. and Kon, O.M. (2021) Personalised Medicine for Tuberculosis and Non-Tuberculous Mycobacterial Pulmonary Disease. Microorganisms, 9, 2220. https://doi.org/10.3390/microorganisms9112220
|
[12]
|
洪青青, 姚超, 张新宝. 非结核分枝杆菌肺病患者流行病学临床特点及耐药情况分析[J]. 中华肺部疾病杂志(电子版), 2022, 15(4): 506-508.
|
[13]
|
Howard, S.T., Rhoades, E., Recht, J., et al. (2006) Spontaneous Reversion of Mycobacterium abscessus from a Smooth to a Rough Morphotype Is Associated with Reduced Expression of Glycopeptidolipid and Reacquisition of an Invasive Phenotype. Microbiology (Reading), 152, 1581-1590. https://doi.org/10.1099/mic.0.28625-0
|
[14]
|
Jarlier, V. and Nikaido, H. (1994) Myco-bacterial Cell Wall: Structure and Role in Natural Resistance to Antibiotics. FEMS Microbiology Letters, 123, 11-18. https://doi.org/10.1111/j.1574-6968.1994.tb07194.x
|
[15]
|
Kang, J.S. and Lee, M.H. (2009) Overview of Therapeu-tic Drug Monitoring. The Korean Journal of Internal Medicine, 24, 1-10. https://doi.org/10.3904/kjim.2009.24.1.1
|
[16]
|
吴菲, 陶丽, 杨泽平, 张雷, 韩鹃. 治疗药物监测在ICU重症感染患者抗菌药物联用的作用[J]. 临床急诊杂志, 2022, 23(11): 781-786.
|
[17]
|
Sotgiu, G., Alffenaar, J.W., Centis, R., et al. (2015) Therapeutic Drug Monitoring: How to Improve Drug Dosage and Patient Safety in Tuberculosis Treatment. International Journal of Infectious Diseases, 32, 101-104.
https://doi.org/10.1016/j.ijid.2014.12.001
|
[18]
|
van Altena, R., Dijkstra, J.A., van der Meer, M.E., et al. (2017) Re-duced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 61, e01400-16. https://doi.org/10.1128/AAC.01400-16
|
[19]
|
Vu, D.H., Alffenaar, J.W., Edelbroek, P.M., et al. (2011) Dried Blood Spots: A New Tool for Tuberculosis Treatment Optimization. Current Pharmaceutical Design, 17, 2931-2939. https://doi.org/10.2174/138161211797470174
|
[20]
|
黄观日, 陆俊江, 王昌伟, 许万群. 连续性血液净化在治疗重症脓毒血症中的临床效果[J]. 吉林医学, 2022, 43(12): 3322-3324.
|
[21]
|
古旭云, 盛博, 陈炜, 赵磊, 牛素平, 李丽娟. 动态监测血清炎症因子在评估脓毒血症严重程度的临床价值[J]. 中国卫生检验杂志, 2015, 25(5): 676-679.
|
[22]
|
郭爱华, 姜勇. 从全身炎症反应综合症到脓毒性休克[J]. 中国危重病急救医学, 2002, 14(8): 500-503.
|